Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neuroectodermal Tumors, Primitive 2Uterine Neoplasms 1Tuberous Sclerosis 1Perivascular Epithelioid Cell Neoplasms 1Neuroendocrine Tumors 1Endometrial Neoplasms 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Angiomyolipoma 1

Interventions

Trastuzumab 303Paclitaxel 256Cyclophosphamide 251Docetaxel 238Capecitabine 175Letrozole 163Carboplatin 163Doxorubicin 145Fulvestrant 144Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 88Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 44Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × dactolisib × Clear all
NCT01288092 2012-06-07

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Novartis

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡